One-year efficacy of tenofovir alafenamide in patients with chronic hepatitis B
Abstract. Non-inferior antiviral efficacy and better renal safety have been reported in chronic hepatitis B patients with tenofovir alafenamide (TAF) treatment. The experience in real-world clinical practice is limited. We aimed to explore the efficacy after 1-year TAF treatment. A total of 148 pati...
| Hlavní autoři: | , , , |
|---|---|
| Médium: | Článek |
| Jazyk: | English |
| Vydáno: |
Wolters Kluwer
2022-06-01
|
| Edice: | Medicine |
| On-line přístup: | http://journals.lww.com/10.1097/MD.0000000000029269 |